{"id":33409,"date":"2014-10-09T09:36:25","date_gmt":"2014-10-09T13:36:25","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=33409"},"modified":"2014-10-09T09:36:25","modified_gmt":"2014-10-09T13:36:25","slug":"ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409","title":{"rendered":"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 <strong>Ocular Therapeutix Inc (NASDAQ:OCUL)<\/strong> said that it has completed the process of enrollment for its two Stage three clinical studies on investigating Sustained Release Dexamethasone or OTOX-DP. The company indicated that the study was meant to treat ocular pain and inflammation after a surgery of cataract.<\/p>\n<p style=\"text-align: justify;\"><strong>One-Time Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">The company stated that OTX-DP should be administrated one-time, and the drug candidate was placed in the canaliculus, its statement revealed. It was designed to provide dexamethasone to the surface ocular for about four weeks. After the treatment, OTX-DP resorbs and leaves the system of nasolacrimal without any need for its removal.<\/p>\n<p style=\"text-align: justify;\">Ocular Therapeutix Inc (NASDAQ:OCUL) said that it was evaluating 486 patients in 32 sites around the United States through the two prospective, randomized, multicenter, double-masked, parallel-arm and vehicle-controlled trials. After the surgery, patients were randomized to get any one of placebo vehicle punctum plug or OTX-DP without any active drug. The company pointed out that the primary efficacy endpoints indicated a reduction in pain on day eight and inflammatory cells in eye\u2019s anterior chamber on day 14.<\/p>\n<p style=\"text-align: justify;\"><strong>FDA Submission Next Year<\/strong><\/p>\n<p style=\"text-align: justify;\">The company said that it was looking forward to presenting the results to the Food and Drug Administration next year.<\/p>\n<p style=\"text-align: justify;\">Ocular Therapeutix Inc (NASDAQ:OCUL) said that generally for treating ocular pain and inflation after an ophthalmic surgery, topical corticosteroids were prescribed. However, it presented a complex regimen that had the potential to lead to lower compliance levels, which would ultimately lead to an adverse outcome.<\/p>\n<p style=\"text-align: justify;\">On the other hand, administering topical corticosteroids could lead to higher intraocular pressure that might stimulate glaucoma. The company said that physicians hold the compliance wherever a physician administers a single-dose corticosteroid. This might also enhances the issue of patient non-compliance as far as dosing regimens were concerned.<\/p>\n<p style=\"text-align: justify;\"><strong>Management Speaks<\/strong><\/p>\n<p style=\"text-align: justify;\">The Ocular Therapeutix Inc (NASDAQ:OCUL)\u2019s President and CEO, Amar Sawhney, said that the completion of enrollment was an extraordinary milestone for the company. He pointed out that it was the first Phase 3 studies ever to be completed for a sustained release.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 Ocular Therapeutix Inc (NASDAQ:OCUL) said that it has completed the process of enrollment for its two Stage three clinical studies [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":33412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[10547,10524,10523,10522],"stock_ticker":[],"class_list":["post-33409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-amar-sawhney","tag-nasdaqocul","tag-ocular-therapeutix-inc","tag-ocular-therapeutix-inc-nasdaqocul","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 Ocular Therapeutix Inc (NASDAQ:OCUL) said that it has completed the process of enrollment for its two Stage three clinical studies [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-09T13:36:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone\",\"datePublished\":\"2014-10-09T13:36:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg\",\"keywords\":[\"Amar Sawhney\",\"NASDAQ:OCUL\",\"Ocular Therapeutix Inc\",\"Ocular Therapeutix Inc (NASDAQ:OCUL)\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\",\"name\":\"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg\",\"datePublished\":\"2014-10-09T13:36:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg\",\"width\":300,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone - Wall Street PR","og_description":"Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 Ocular Therapeutix Inc (NASDAQ:OCUL) said that it has completed the process of enrollment for its two Stage three clinical studies [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-09T13:36:25+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone","datePublished":"2014-10-09T13:36:25+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg","keywords":["Amar Sawhney","NASDAQ:OCUL","Ocular Therapeutix Inc","Ocular Therapeutix Inc (NASDAQ:OCUL)"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409","url":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409","name":"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg","datePublished":"2014-10-09T13:36:25+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/OCULAR.jpg","width":300,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ocular-therapeutix-inc-nasdaqocul-closes-enrollment-for-its-two-stage-three-clinical-study-on-sustained-release-dexamethasone-33409#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix Inc (NASDAQ:OCUL) Closes Enrollment For Its Two Stage Three Clinical Study On Sustained Release Dexamethasone"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=33409"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33409\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/33412"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=33409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=33409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=33409"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=33409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}